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Abstract
Introduction: Personalization of pharmacotherapy of cardiovascular diseases is one of the urgent problems of cardi-
ology.
Material and methods: The study includes 120 patients with grades 2-3 arterial hypertension with the criteria of high 
and very high risk of developing cardiovascular complications. The patients were randomized into three groups with 
differentstarting regimens of pharmacotherapy – fixed and free combinations of ACE inhibitors and dihydropyridine 
CCB. Evaluation of the efficacy, safety and individualization of a therapy was carried out by using pharmacokinetic, 
pharmacoeconomic, sonographic, and laboratory methods.
Results and discussion: Antihypertensive treatment with the inclusion of Amlodipine and Lisinopril or Ramipril in pa-
tients with arterial hypertension, having a slow and very slow oxidative metabolism phenotype, is characterized by the 
development of a more pronounced hypotensive effect in this group of patients (p<0.05-0.001)  (Δ% SBP from 12.7 to 
24.6 and from 19.6 to 27.9, respectively; Δ% DBP from 10.6 to 19.1 and from 15.9 to 23.6, respectively) in comparison 
to the group of patients with a fast phenotype (Δ% SBP from 6.42 to 9.34; Δ% DBP from 1.04 to 5.66), which allows 
administering a personalized pharmacotherapy. For patients with arterial hypertension of high and very high risk, the 
use of a fixed combination of Amlodipine and Lisinopril as a basic variant of the two-four-component therapy com-
pared with treatment options based on free combinations of the studied drugs provided a significantly more pronounced 
decrease in systolic blood pressure (24.9%, 17.8 %, 19.0%, respectively, p<0.01), a greater degree of regression of 
left ventricular myocardial hypertrophy (8.70%, 5.67%, 5.84%, respectively, p<0.05), significant (p<0.05-0.001) im-
provement in a number of parameters of the patients’ quality of life, and was characterized by the greatest economic 
efficiency according to various criteria of hypotensive action.
Conclusion: The results obtained in the study demonstrate the advantages of a fixed combination over free combina-
tions of antihypertensive drugs and demonstrate the possibility of a pharmacokinetic approach to individualization of 
pharmacotherapy.
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Introduction
The results of large controlled clinical studies indicate 
that in order to achieve the optimal control of blood pres-
sure, a significant number of patients with high and very 
high risk hypertension have to at least two antihyperten-
sive drugs at the same time take (Berglund 1989, Dyadik 
et al. 2013).
However, the complexity of the simultaneous adminis-
tration of several drugs and the increased costs for them in 
some cases significantly reduce the patients’ adherence to 
treatment. One of the ways to solve this problem is to use 
fixed combinations of drugs.
One of today’s leading combinations providing a posi-
tive effect on the outcome for patients with hypertension 
is a combination of an ACE inhibitor and CCB. The effi-
cacy of this combination of drugs, in particular the com-
bination of Amlodipine and Lisinopril, due to their effect 
on surrogate and final points in patients with hypertension 
has been shown in many studies (Elliott  2006, Nedogoda 
et al. 2013, Protasov et al. 2009).
Despite this, approaches to individualization of phar-
macotherapy of patients with high and very high hyper-
tension by means of fixed combinations in comparison 
with free combinations of antihypertensive drugs are not 
well studied, either in terms of pharmacodynamic features 
affecting the quality of patients’ life, or in terms of phar-
macoeconomic analysis.
In the Russian Federation, the annual economic da-
mage caused by temporary or permanent disability asso-
ciated with hypertension or its complications, as well as 
the costs of treatment and rehabilitation of this category 
of patients exceed 30 billion rubles, and the costs are 
constantly increasing. In this regard, the choice of drugs 
optimal both in terms of clinical and pharmacoeconomic 
effectiveness is one of the most important medical and 
social problems (Chazova and Oshepkova 2013, Glezer 
et al. 2014, Karpov 2001).
At the same time, one of the possibilities to reduce 
patient’s expenses for drug therapy is the use of fixed 
combinations of antihypertensive drugs (Kolosov and 
Proshin 2016). The studies mentioned earlier demonstra-
ted the cost-effectiveness of such an approach. It turned 
out that the separate use of drugs compared with the fixed 
combinations of the same substances was accompanied 
by significantly higher total cost of patient management 
(Markova et al. 2012, Petrov 2002).
Despite numerous studies on this issue, a number of 
issues remains controversial and unresolved.
Along with clinical and social factors, one of the most 
important modern trends is the substantiation of the eco-
nomic aspects of the strategy and tactics of treatment, 
including patients with hypertension. From this point of 
view, the task of comprehensive integrated assessment of 
the optimal ratio of the price of drugs and their efficacy 
requires its solution, which will contribute to the efficacy 
of treating patients with hypertension (Gilyarevsky and 
Golshmid  2016, Reshetko et al. 2015).
Development and implementation of personalized 
pharmacotherapy should use innovative techniques. 
Earlier studies have established heterogeneity of the 
humans in their ability to metabolize drugs. Currently, 
the individualization of pharmacotherapy of circulatory 
system diseases is mainly based on pharmacodynamic 
and pharmacogenetic approaches. The latter is the most 
promising, but technically more complex. Keeping in 
mind the coincidence of biotransformation pathways 
of antihypertensive drugs and markers, the evaluation 
of polymorphism of oxidative metabolism based on 
the study of pharmacokinetics of the test-drug, from a 
practical point of view, is one of the ways to persona-
lize pharmacotherapy. Among the main classes of an-
tihypertensive drugsб there are medicinal substances, 
pharmacodynamic effect from which is determined by 
the characteristics of their pharmacokinetics, in particu-
lar, the genetically determined rate of biotransformation 
processes. One of such drugs is Amlodipine. It seems 
practically important to study the intensity of pharmaco-
dynamic effects of the combination therapy of Amlodi-
pine and the representatives of one of the leading classes 
of antihypertensive agents – ACE inhibitors in patients 
with hypertension, having different oxidative metabo-
lism phenotypes (Borodulin et al. 2012, Kazakov and 
Sycheva 2015, Knott et al. 1984, Sychev et al. 2011).
At the same time, the data available in the literature do 
not fully represent the whole range of possible approa-
ches to the personalization of antihypertensive therapy in 
patients with high and very high risk hypertension, based 
on a systematic analysis of the intensity of the pharmaco-
dynamic effect of treatment in various phenotypic groups 
of patients with different oxidative metabolism rate; the 
nature of the drugs used and their combinations; and the 
use of mathematical methods for predicting the hypoten-
sive effect of the therapy.
The information above confirms the relevance of the 
problem under study and serves as a rationale for the re-
search undertaken.
Objective: to conduct a comparative evaluation of the 
pharmacological and pharmacoeconomic efficacy of va-
rious regimens of the combined antihypertensive therapy 
in patients with high and very high risk arterial hyperten-
sion; to study the possibility of using a pharmacokinetic 
approach to personalize the pharmacotherapy in a speci-
fied contingent of patients.
Material and methods
General characteristics of patients
The design of the research is an open, randomized study 
in parallel groups of patients.
Criteria for inclusion into the study: men and women 
aged 45-65 years with grades 2-3 arterial hypertension, 
having a high and very high risk of developing cardiovas-
cular complications (Diagnosis and Treatment of Hyper-
tension. Russian Recommendations 2010).
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Сriteria for exclusion from the study: the presence of 
heart disease, myocardial infarction, stroke, classes III-
IV stable exertional angina, during the examination or in 
the medical history; the presence of classes III-IV chronic 
heart failure, cardiac arrhythmias and conduction distur-
bances requiring antiarrhythmic therapy; symptomatic 
arterial hypertension; the presence of chronic broncho-
pulmonary pathology, diabetes; comorbidities requiring a 
constant medical therapy.
The study involved 120 patients. The average age of 
patients was 63.0 [58.0; 64.0] years; the duration of ar-
terial hypertension was 10.6±2.89 years. Men made up 
70% (84 people), women - 30% (36 people). Among the 
patients included in the study, the patients with grade 3 
hypertension (95 people, 79.9.1%) prevailed, 25 patients 
(20.9%) had grade 2 hypertension. High risk was deter-
mined in 58 people (48.3%), very high – in 62 patients 
(51.7%). Class II stable angina pectoris was diagnosed in 
32 patients (26.6%). In 36 patients (30%), class I CHF 
was registered, in 84 patients (70%) – class II CHF.
Clinical, laboratory and instrumental methods of the 
study were used in the patients eligible for inclusion into 
the main group over a three-day placebo period, and then 
the patients were randomized into three groups with dif-
ferent pharmacotherapy regimens (Fig. 1). The stratifi-
cation criteria for randomization were: gender (men/wo-
men), age (below 55 years old/over 55 years old), grade 
of hypertension (2/3 grade), presence or absence of stable 
angina, functional class of CHF (class I/II). The patient 
groups were comparable (p>0.05) with one another by 
the parameters under study. All the patients prior to the 
introductory period had signed the informed consent on 
the participation in the study.
After the randomization, in each of the three groups, 
doses of drugs were titrated and the stages of therapy 
were changed with 2-week interval. The criteria for in-
creasing doses of drugs or switching to a higher stage of 
pharmacotherapy was failure to achieve the target blood 
pressure – under 140/90 mm Hg – evaluated at the next 
patient’s visit. Upon reaching the fourth stage of therapy, 
this scheme was followed for 6 weeks. The total duration 
of follow-up was 14 weeks.
For the pharmacological correction of hypertension, 
the following drugs were used: Amlodipine (Normodi-
pine, Gedeon Richter Ltd., Hungary), Ramipril (Ampri-
lan, KRKA Ltd., Slovenia), Lisinopril (Diroton, Gedeon 
Richter Ltd., Hungary), fixed combination of Amlodipine 
and Lisinopril (Eqvator, Gedeon Richter Ltd., Hungary), 
Bisoprolol (Bidop, Gedeon Richter Ltd., Hungary), Inda-
pamid (Indapamid MV, STADA, Makiz-Pharma Ltd., 
Russia).
In addition to antihypertensive therapy, the patients 
received lipid-lowering therapy – statins (Atorvastatin or 
Rosuvastatin) in appropriately selected doses; antiplate-
let agents (Acetylsalicylic acid, 75mg/day) when there no 
contraindications. In the screening period, if necessary, 
the patients could use Captopril and short-acting nitrova-
sodilators.
Methods for assessing the morphofunctional parame-
ters of the circulatory system, daily blood pressure 
profile, laboratory parameters, phenotype of oxidative 
metabolism, characteristics of the quality of life of pa-
tients with arterial hypertension
Evaluation of casual (“office”) values of blood pressure 
was carried out according to the existing methodological 
requirements. The initial level of systemic hemodynamic 
parameters were the ones recorded before the start of 
pharmacotherapy.
Figure 1. Design of an open, randomized study of pharmacological correction of hypertension in parallel groups of patients.
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The diurnal profile of blood pressure was assessed 
using a BPLab MnSDP-1 monitor (Petr Telegin Ltd., 
Russia) according to the generally accepted method 
(Rogoza 1997), with the following parameters deter-
mined: the mean level of SBP, DBP, HR during day-
time, nighttime and 34-hour periods; variability of SBP 
and DBP during daytime and nighttime; systolic and 
diastolic blood pressure loads; daily indices of SBP and 
DBP.
The study of the structural and functional parameters 
of the heart and blood vessels was performed by using 
a sonographic method on an SSI-8000 SonoScape ultra-
sound system (Sono Scape Co. Ltd, PRC). Doppler echo-
cardiography was carried out according to the standard 
technique. When assessing the structural parameters of 
the brachiocephalic vessels, a transverse and longitudinal 
scanning of the middle third of the right and left common 
carotid arteries was performed, measuring the thickness 
of the intima-media complex and the subsequent calcu-
lation of the average values of the index (Atkov 2015, 
Devereux et al. 1986).
The laboratory tests included an assessment 
of complete blood and urine analyses; biochemi-
cal blood parameters (total cholesterol, triglyceri-
des, HDL cholesterol, glucose, creatinine, sodium, 
potassium), determined by means of an automatic 
analyzer Furuno-CA-180 (Furuno Electric Co, Japan). 
The calculation of lipid-transport system parameters was 
carried out according to the standard formulas.
The quality of life of patients with hypertension was 
assessed using the SF-36 questionnaire. At the same 
time, psychosocial and physical status of patients was 
determined, described by the following scales: physical 
functioning (PF), role-based physical functioning (RPF), 
pain (P), vitality (V), social functioning (SF), role-based 
emotional functioning (REF), and mental health (MH) 
(Novik 2007).
The phenotype of oxidative metabolism was studied 
on the basis of the assessment of the pharmacokinetic pa-
rameters of the drug marker (Aminophylline), determin-
ed in biofluid (saliva) by the method of highly effective 
reversed-phase liquid chromatography (Milichrom chro-
matograph, Nauchpribor Ltd., Russia). The test indicator 
for determining the phenotype of oxidative metabolism 
was the half-life of the test drug: T1/2 under 9 hours – pa-
tients with a rapid phenotype of oxidative metabolism; 
T1/2 = 9–15 hours – people with a slow phenotype; T1/2> 
15 hours – patients with a very slow rate of oxidative 
metabolism (Kachmarskaya 1996).
The above research methods, as well as electrocar-
diography (electrocardiographs EK 12 T-01- RD, RF, 
SchillerAT-1, SCHILLERAG, Switzerland) were used 
in a placebo period and at the end of the 14th week of 
pharmacotherapy (except for the pharmacokinetic stu-
dy). At the end of the 4th week of pharmacotherapy, the 
“office” values of blood pressure and heart rate were 
evaluated, and the 24-hour blood pressure monitoring 
was performed.
Methods of pharmacoeconomic and statistical data 
analysis
Pharmacoeconomic analysis was carried out using the 
method of “cost-effectiveness” (Industry Standard IS 
91500.14.0001-2002 ”Clinical and economic research. 
General provisions” 2002).
Due to the fact all the patients were placed in the equal 
conditions, provided by the design of the study and dif-
ferent only by the nature of the pharmacotherapy, direct 
expenses on medicines were considered as expenses. 
The data for calculating the expenses was obtained on 
the website www.apteka.ru from the price list adapted to 
Kursk region. 
Mathematical data processing was carried out using 
the methods of parametric and non-parametric statistics, 
depending on the nature of the parameter distribution. 
The data in the study is presented in the form of M±SD 
(with a normal distribution) or the median and interquar-
tile interval (with a distribution different from the norm). 
Differences were considered statistically significant with 
bilateral values of p<0.05. To eliminate erroneous esti-
mates of the reliability of differences in parameters, in 
the multiple comparison of subgroups, the Bonferroni 
correction was used.
When comparing discrete quantities in a four-field 
table system using the χ2 criterion, the latter was eva-
luated with Yates’ continuity correction. The presence 
and degree of the connection between the various para-
meters was assessed using a correlation analysis. To as-
sess the significance of the influence of various factors 
on the studied parameters, we used analysis of variance. 
The determination of the degree of determinateness of 
the criterion (dependent) variable by predictors (indepen-
dent variables), as well as the prediction of the value of 
the dependent variable using independent variables, was 
carried out using regression analysis.
Results and discussion
Comparative effectiveness of the studied pharmaco-
therapy regimens in patients with high and very high 
risk hypertension
The pharmacodynamic effects of the studied pharmaco-
therapy regimens were evaluated at period of 4 (compa-
rative evaluation of various options for the second stage 
of therapy) and 14 weeks (comparison of treatment regi-
mens in the form of double, triple and quadrotherapy). 
In patients in each of the studied groups, both 4 and 14 
weeks of therapy were accompanied by a significant de-
crease in blood pressure, heart rate, which was most pro-
nounced at the end of the observation period (Table 1).
Comparative intergroup assessment of the intensity of 
the antihypertensive effect of different pharmacotherapy 
options at the end of the 4th week of treatment demonstra-
ted the advantage of the fixed combination of Amlodipine 
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and Lisinopril compared with their free combination, as 
well as with the combination of Amlodipine and Rami-
pril in relation to the degree of SBP reduction (-20.4%, 
-12.1%, -12.3 %, respectively, p<0.001). No significant 
differences between the groups by the DBP dynamics 
(-14.1%, -9.9%, -9.9%, respectively, p>0.05) and heart 
rate (-4.5%, -3.0%, -3.5%, respectively, p>0.05) were 
found. A similar pattern was notoced when comparing the 
degree of reduction in blood pressure and heart rate at the 
end of the 14th weeks of therapy. In the patients of Group 
3, there was a significantly more pronounced decrease in 
SBP in comparison with the patients of Groups 1 and 2 
(-24.9%, -19.0%, -17.8%, respectively, p<0.01), with 
insignificant differences in the degree of DBP (-19.1%, 
-16.6%, -17.4%, respectively, p>0.05) and heart rate 
(-12.1%, -11.7%, -11.1%, respectively, p>0.05). 
The number of patients who reached the target level 
of blood pressure when using the second stage of phar-
macotherapy was more significant in Group 3 (32.5%) 
compared with both Group 1 (10%, p<0.05) and Group 
2 (12.5%, p>0.05). At the end of the 14th week of treat-
ment, the difference between the groups in the number 
of patients having the target level of blood pressure was 
statistically unreliable (47.5%, 47.5%, 67.5%: in Groups 
1, 2 and 3, respectively).
Evaluation of changes in the diurnal profile of blood 
pressure showed that all three groups had a positive re-
liable (p<0.05-0.001) dynamics of the main indicators 
of the 24-hour blood pressure monitoring in each of the 
analyzed periods of the day. Only the change in the daily 
index of blood pressure and parameters of blood pressure 
variability was insignificant (p>0.05). When conducting 
an intergroup comparison of the dynamics of ABPM indi-
cators at the end of the 4-week therapy, significant diffe-
rences were identified in relation to some parameters. In 
the patients of Group 3, in comparison with Group 1 and 
Group 2, the following parameters decreased more sig-
nificantly: SBPd (Δ% 21.3 [11.5; 25.8], 11.9 [6.4; 18.5], 
13.1 [7.2; 17.0], р<0.01, р<0.01, respectively), DBPd 
(Δ% 16.7 [7.0; 26.8], 12.3 [1.08; 18.9], 9.1 [2.5;14.7], 
р>0.05, р<0.01, respectively), TISBPd (Δ% 61.0 [15.5; 
75.5], 12.8 [2.0; 34.0], 18.4 [3.0; 30.4], р<0.001, р<0.001, 
respectively), TIDBPd (Δ% 29.1 [13.3; 90.8], 24.3 [5.42; 
52.9], 25.0 [5.2; 43.2], р>0.05, р<0.05, respectively), 
DBPn (Δ% 16.9 [6.7; 28.9], 11.4 [4.50; 22.4], 8.1 [-2.2; 
18.9], р>0.05, р<0.01, respectively), SPB24h (Δ% 19.8 
[10.2; 26.4], 13.4 [7.0; 17.9], 12.9 [7.5; 18.7], р<0.01, 
р<0.01, respectively), TISBP24h (Δ% 35.5 [7.6; 63.0], 
11.6 [1.0; 31.0], 13.4 [2.5; 28.5], р<0.01, р<0.01, respec-
tively). At the end of the 14th week of therapy, the diffe-
rences between the groups were more leveled. In Group 
3, comparing to Groups 1 and Group 2, the following 
parameters decreased more significantly: SBPd (Δ% 27.9 
[14.3; 30.9], 17.6 [14.2; 25.9], 17.7 [11.3; 25.9], р<0.05, 
р<0.05, respectively), TISBPd (Δ% 86.7 [16.5; 93.6], 
38.1 [7.5; 59.5], 43.4 [8.5; 70.0], р<0.01, р<0.05, respec-
tively), TISBPn (Δ% 54.0 [3.5; 87.0], 22.0 [0.0; 52.5], 
28.5 [0.0; 70.9], р<0.05, р>0.05, respectively), SBP24h 
(Δ% 26.0 [15.0; 31.9], 20.0 [11.1;25.8], 19.5 [12.2; 25.8], 
р<0.01, р<0.05, respectively).
The free combinations of Amlodipine and Lisinopril 
or Ramipril under study were comparable to one another 
in terms of pharmacodynamic effects both as the second 
stage of therapy in patients with high and very high risk 
Table 1. Dynamics of Casual Values of Blood Pressure and Heart Rate in the Process of Pharmacotherapy in Patients of the Studied 
Groups.
Indicators Study period р
Before treat-
ment
4 weeks of 
treatment
14 weeks of 
treatment
1-2 1-3 2-3
1 2 3
Group 1
SBP mm Hg 183.0±10.2 160.2±12.2 148.0±14.3 ***** ************** ***
DBP mm Hg 106.8±6.59 96.0±6.22 88.7±9.18 *** *** ***
Heart rate bpm 82.0±6.39 79.1±8.74 72.3±9.90 * *** ***
Group 2
SBP mm Hg 180.0±5.41 158.0±10.8 148.0±14.9 *** **** ***
DBP mm Hg 106.6±5.79 95.8±6.39 87.7±9.53 *** *** ***
Heart rate bpm 79.4±6.71 76.7±5.05 70.3±7.85 * *** ***
Group 3
SBP mm Hg 183.1±9.16 145.7±17.3 137.5±19.1 *** *** ***
DBP mm Hg 104.7±6.27 89.6±9.96 84.5± 9.72 *** *** ***
Heart rate bpm 79.6±9.09 75.6±7.15 69.6±8.45 ** *** ***
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hypertension, and as the addition to the starting treatment 
regimens with beta-blockers and diuretics. However, both 
treatment options were inferior (p<0.01–0.001 to the fixed 
combination – Amlodipine and Lisinopril – in terms of the 
intensity of the hypotensive effect (degree of SBP reducti-
on), frequency of early (by the end of the 4th week) achie-
vement of the target level of BP. Moreover, this advan-
tage was implemented with a more frequent prescription 
of the second stage of treatment to the patients of Group 
3. A more pronounced and early achievement of a signi-
ficant antihypertensive effect due to the optimization of 
combination therapy, is especially important for patients 
with grades 2-3 hypertension, because most of them have 
structural and functional changes in their target organs.
The results of the present study are comparable with 
the literature data showing that the fixed combination of 
Amlodipine and Lisinopril has high antihypertensive effi-
cacy compared with other combinations of antihyperten-
sive drugs. This fact was recorded both according to the 
daily monitoring of blood pressure, and during its routine 
measurement (Nedogoda et al. 2013, Ostroumova et al. 
2017).
Thus, the use of a fixed combination of Amlodipine 
and Lisinopril, both as a starting therapy for patients with 
hypertension of high and very high risk, and in combina-
tion with drugs of the third and fourth stages of treatment, 
resulted in a more pronounced hypotensive effect and a 
more frequent early (at the end of the 4th week of therapy) 
achieving the target level of blood pressure.
Assessment of the effect of the oxidative metabolism 
phenotype on the intensity of the hypotensive effect of 
drugs used in patients with high and very high risk 
hypertension
The ability to conduct an analysis assessing the effect of 
a genetically determined rate of oxidative metabolism on 
the degree of hypotensive effect of the drugs used in the 
study was possible due to their pharmacokinetic charac-
teristics. The latter was due to the fact that the only drug 
used (when implementing the second stage of pharmaco-
therapy), the pharmacodynamic effect of which depended 
on the rate of oxidative metabolism determined by the 
test drug, was Amlodipine. According to the literature, 
members of individual families and subfamilies, as well 
as individual isoenzymes of cytochrome P450, could have 
a “cross” substrate specificity, which made it possible to 
carry out an indirect assessment of the activity of one 
isoenzyme according to the test results of another using 
a marker drug (Beresford et al. 1988, Sychev et al 2007).
The data on the degree of reduction in blood pressu-
re (presented in modular values) in different phenotypic 
groups in patients who had been receiving various options 
for the second stage of pharmacotherapy, are reflected in 
Table 2.
As follows from the data presented, the degree of BP 
reduction in patients with a slow and very slow phenotype 
of oxidative metabolism was significantly higher than that 
in patients with a fast variant of the oxidative process. 
The first two phenotypic groups also differed significantly 
from each other in terms of SBP reduction, except for the 
cohort of patients who had received a fixed combination 
of Amlodipine and Lisinopril. According to Δ% DBP, no 
significant differences between the slow and very slow 
oxidation phenotypes were found.
The degree of decrease in blood pressure in patients of 
Grup 1 with slow and very slow phenotypes of oxidative 
metabolism was significantly higher than that in patients 
with a fast variant of the oxidative process. The first two 
phenotypic groups also significantly differed by the de-
gree of reduction of systolic blood pressure. In terms of a 
decrease in diastolic blood pressure, there were no signi-
ficant differences between the slow and very slow pheno-
types of oxidative metabolism.
Statistical analysis, evaluating the intensity of a decre-
ase in blood pressure in various phenotypic groups in pa-
tients who received the free combination of Amlodipine 
and Lisinopril as starting therapy, revealed a relationship 
Table 2. Degree (%) of Blood Pressure Reduction in Patients with Different Phenotypes of Oxidative Metabolism in the Studied 
Groups.
Intervention 
groups
Indicators Phenotypic groups р
F S VS 1-2 1-3 2-3
1 2 3
Group 1 Δ%SBP 6.42 [3.90;8.85] 12.7±3.5 19.6±5.66 ** *** ***
Δ%DBP 5.66 [0.39;8.16] 10.6±6.39 16.6±5.14 * *** na
Group 2 Δ%SBP 6.59 [4.07;6.59] 13.1±1.73 21.6±3.09 *** *** ***
Δ%DBP 5.66 [0.90;5.66] 11.9±5.43 15.9±3.83 *** *** na
Group 3 Δ%SBP 9.34 (6.25-14.1) 24.6±4.41 27.9±6.54 *** *** na
Δ%DBP 1.04 (-4.17-5.66) 19.1±5.70 23.6±8.66 *** *** na
Note. F - fast phenotype of oxidative metabolism,  S - slow phenotype of oxidative metabolism, VS - very slow phenotype of oxi-
dative metabolism.
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similar to the one observed in patients of the first inter-
vention group. In Group 3, patients who had slow and 
very slow oxidative metabolism phenotypes were iden-
tical (p> 0.05) to each other in terms of blood pressure 
reduction in a 4-week therapy with a fixed combination of 
Amlodipine and Lisinopril and significantly outnumbered 
individuals with a high oxidation rate. 
Gradations of the oxidative metabolism rate, conside-
red as a determining factor when conducting analysis of 
variance, had a significant effect on the degree of reduc-
tion in SBP and DBP: for Group 1 – F = 18.7, p<0.001, 
F = 9.89, p<0.001, respectively; for Group 2 – F = 46.1, 
p<0.001, F = 14.1, p<0.001, respectively; for the patients 
of Group 3 – F = 39.9, p<0.001, F = 33.0, p<0.001, res-
pectively.
A correlation analysis evaluating the interrelation of T1/2 
of the test drug and the degree of antihypertensive effect 
of therapy established a significant effect of the studied 
parameter on Δ% SBP and Δ% DBP in patients of Group 1 
(r = 0.59, p<0.001; r = 0.58, p<0.001, respectively ); simi-
lar data were obtained from patients of Group 2 (r = 0.83, 
p<0.001; r = 0.60, p<0.001, respectively) and Group 3 (r = 
0.55, p<0.001; r = 0.64, p<0.001, respectively).
The main objective of the regression analysis was the 
construction of regression equations, which make it pos-
sible to predict the intensity of the hypotensive effect with 
considerable probability when the second stage of therapy 
was used as the starting one, based on the free or fixed 
combination of Amlodipine with Lisinopril or Ramipril. 
In this case, the dependent parameter was the degree of 
reduction in SBP and DBP, and the half-life of the test 
drug and baseline BP values served as independent indi-
cators. Regression analysis was performed with respect 
to the indicated parameters, assessed at the end of the 
4-week therapy, since in that case the use of regression 
equations would allow to predict the efficacy of pharma-
cotherapy and optimize the choice of starting treatment 
options. The choice of parameters for regression analy-
sis depended on the presence of a significant correlation 
between pharmacokinetic and hemodynamic parameters. 
In addition to the above-mentioned correlations between 
T1/2 and Δ%BP, the latter was determined by its initial le-
vel. When evaluating the 4-week treatment of patients of 
Group 1, Δ% SBP reliably correlated with the initial value 
of the SBP (r = 0.32, p<0.05), Δ% DBP – with the initial 
level of DBP (r = 0.63, p<0.001). In Group 2, the initi-
al levels of SBP and DBP were significantly correlated 
with the magnitude of their decrease (r = 0.41, p<0.01, r 
= 0.54, p <0.001, respectively). The initial SBP level in 
patients of Group 3 did not have a significant correlation 
with Δ% SBP (r = 0.055, p>0.05), while the baseline va-
lues of DBP significantly correlated with the magnitude 
of their decrease (r = 0.45, p<0.01).
Indicators of regression analysis carried out in the 
studied groups of patients, characterizing the intensity 
of the linear relationship between dependent (Δ% SBP, 
Δ% DBP) and independent (T1/2 initial levels of SBP and 
DBP) variables indicate its reliability (Table 3).
The regression equations, allowing calculating the pre-
dicted hypotensive effect of the 4-week therapy, were as 
follows: 
for the free combination of Amlodipine and Ramipril
 Δ%SBP= -57.9+0.995·Т1/2+0.318·SBPini;
 Δ%DBP= -64.5+0.758·Т1/2+0.611·DBPini,
for the free combination of Amlodipine and Lisinopril
 Δ%SBP= -62.9+1.032·Т1/2+0.352· SBPini;
 Δ%DBP= -83.8+0.967·Т1/2+0.775· DBPini,,
for the fixed combination of Amlodipine and Lisinopril
 Δ%SBP= -37.4+1.149·Т1/2+0.247· SBPini;
 Δ%DBP= -78.7+1.398·Т1/2+0.741· DBPini,
where SBPini и DBPini – initial levels of SBP and DBP, 
respectively. 
Table 3. Results of the Regression Analysis of the Dependence of Δ% BP on its Initial Level and the T1/2  of Test Drug in the Studied 
Patients During the 4-week Pharmacotherapy.
Regression Analysis Criteria Δ%SBP Δ%DBP
Group 1
Multiple correlation coefficient (R) 0.778 0.791
Determination coefficient (R2) 0.606 0.625
F-criterion 28.4 23.4
р F-criterion <0.001 <0.001
Group 2
Multiple correlation coefficient (R) 0.880 0.860
Determination coefficient (R2) 0.770 0.750
F-criterion 63.0 54.6
р F-criterion <0.001 <0.001
Group 3
Multiple correlation coefficient (R) 0.60 0.770
Determination coefficient (R2) 0.360 0.590
F-criterion 10.5 27.2
р F-criterion <0.001 <0001
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In the regression equations calculated for Groups 1 and 
2, all β-coefficients of the equations were highly signifi-
cant (p<0.001). The coefficient of determination explain-
ed more than 60% of variations of the dependent variable 
in Group 1 and not less than in ¾ patients of Group 2. 
In the formula for calculating Δ% SBP for Group 3, the 
intercept of the equation and the β-coefficient SBPini were 
statistically insignificant. However, the exclusion of the 
initial values  of the SBP from the parameters of the re-
gression equation led to the deterioration of the latter, and 
therefore this indicator was left in the list of independent 
parameters of the regression equation. The constructed 
equation was not characterized by a high degree of co-
verage of the variation of Δ%SBP, but it was also reliable. 
The coefficient of determination of the equation for cal-
culating the Δ% DBP in the Group 3 of patients explained 
the variations in the dependent variable in more than half 
of the patients in Group 3. All β - coefficients of this equa-
tion were highly significant (p<0.001).
The reduction of the forecast accuracy (by the variable 
component) of a decrease in blood pressure to the average 
value for all the three options of starting pharmacotherapy 
is characterized by a rather high percentage – 61.7% – of 
the sample of patients with high and very high risk of AH 
who will have a coincidence of theoretical and actual va-
lues Δ% BP.
Thus, the conducted multivariate analysis showed the 
dependence of the degree of blood pressure reduction on 
the phenotypic variant of oxidative metabolism, assessed 
during the 4-week treatment of hypertensive patients with 
different second-stage antihypertensive therapy with Am-
lodipine and Lisinopril or Ramipril. Personalization of 
antihypertensive therapy could be achieved by assessing 
the phenotype of oxidative metabolism in patients with 
hypertension using drugs, pharmakokinetics of which 
ensured the polymodal nature of the pharmacodynamic 
response of patients to pharmacological intervention. 
Adequate prediction of the hypotensive effect could be 
achieved in almost 2/3 of patients using regression equa-
tions obtained in the study.
The influence of various variants of combined phar-
macotherapy on the morphofunctional parameters 
of the cardiovascular system, laboratory parameters, 
quality of life of patients with high and very high risk 
hypertension
The structural parameters of the left ventricle in patients 
with high and very high risk hypertension favorably 
changed during the 14-week therapy in all the three inter-
vention groups. The main criterion of LV myocardial hy-
pertrophy – MMI decreased in patients of Group 1 from 
153.5326.2 to 144.8±27.3 g/m2 (p<0.001), in Group 2 – 
from 153.7±25.6 to 144.9±24.8 g/m2 (p<0.001), in Group 
3 – from 150.5±28.7 to 137.4±28.0 g/m2 (р<0.001). In-
tergroup analysis revealed the priority of the treatment 
regimen used in Group 3 of patients according to the 
impact on the degree of left ventricular IMM reduction 
in comparison with the pharmacotherapy options of pa-
tients in Groups 1 and 2. The integral parameter reflecting 
the systolic function of the LV – EF increased equally in 
each of the three studied groups of patients (in Group 1 
from 62.9±4.13 to 63.7±4.73%, p<0.05; in Group 2 from 
62.8±5.73 to 63.4±5.49%, p<0.05; in Group 3  from 
63.3±4.69 to 64.5±4.51%, p<0.01). The thickness of the 
carotid intima-media complex did not significantly chan-
ge during the observation period. 
The study showed a positive effect of the used treat-
ment regimens for patients with hypertension, on the 
structural indicators of the heart – regression of LV myo-
cardial hypertrophy. The literature data on the timing 
of the development of LVH regression in patients with 
hypertension under the influence of pharmacotherapy is 
quite contradictory. Many researchers believe that a signi-
ficant reduction in LVMM can be obtained at least after 6 
months of treatment. At the same time, there are a number 
of studies, where an earlier (after 3-4 months) statistically 
significant change in the value of the structural parame-
ters of the heart was shown.The study by Ostroumova et 
al. (2017) shows that fixed combinations (Amlodipine 
and Lisinopril; Bisoprolol and Hydrochlorothiazide) sta-
tistically significantly reduced the severity of LVH (mo-
reover, the A/L combination did significantly better), ha-
ving reduced the left ventricular myocardial mass index 
and left ventricular wall thickness, despite the relatively 
small period (12 weeks).
A fairly rapid and significant regression of the left ven-
tricular MMI in patients with hypertension can be caused 
by various factors, in particular, the presence of baseline 
LVH, a combination of drugs that have the most pronoun-
ced effect on the regression of LV myocardial hypertrop-
hy (Kakhramanova and Bakhshaliev 2008, Prokofyeva 
and Glezer 2015, Terpstra et al. 2001). The basic combi-
nations of the drugs used in the study –  ACE inhibitors 
and CCB – are leaders by their ability to reduce the LV 
myocardium mass (Fagard et al. 2009).
Dynamic control of biochemical blood parameters indi-
cated the absence of a negative effect of the used pharma-
cotherapy on the studied parameters. A number of blood 
lipid spectrum indicators had a significant positive trend 
when using each of the three pharmacotherapy regimens: 
in Group 1, the cholesterol level decreased from 6.43±0.80 
to 6.0±0.74 mmol/l (p<0.001), LDL – from 4.41±0.92 to 
3.89±0.84 mmol/l (p<0.001); in Group 2, cholesterol – 
from 6.14±0.96 to 5.91±0.84 mmol/l (p<0.01), cholesterol 
LDL – from 3.97±0.91 to 3.80±0.82 mmol/l (p<0.05); 
in Group 3, cholesterol –  from 6.36±0.86 to 5.81±0.79 
mmol/l (p<0.001), cholesterol LDL – from 4.39±0.88 to 
3.79±0.88 mmol/l (p<0.001). This effect was caused by 
several factors: the used lipid-lowering therapy, metabo-
lic neutrality and pleiotropic effects of the hypotensive 
agents used. A more pronounced (p<0.05-0.01) decrease 
in LDL cholesterol was observed in patients of Groups 1 
and 3 compared to the patients of Group 2.
The biochemical parameters evaluated in the present 
study did not undergo any negative changes in the treat-
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ment process of each of the three studied treatment regi-
mens. The positive dynamics of the indicators of the lipid 
and carbohydrate metabolism, recorded in the paper may 
be the result of the administration of the basic therapy 
(statins), the presence of metabolic neutrality and pleiot-
ropic effects in the used drugs.
The indicators of the quality of life of patients, asses-
sed over the entire observation period, were characterized 
by significant (p<0.001) positive dynamics in both mental 
and physical health parameters in each of the three obser-
vation groups. The use of a fixed combination of Amlodi-
pine and Lisinopril as a basic treatment option for patients 
with hypertension compared to free combinations of ACE 
inhibitors and CCB allowed for a more significant impro-
vement in a number of parameters of patients’ quality of 
life: pain scale, general health, social functioning, and 
mental health (Fig. 2). The scale of physical functioning 
was significantly higher in patients of Group3 compared 
with Group 2.
In the study performed, the indicators of the quality 
of life of the examined patients, assessed over the entire 
observation period, were characterized by significant po-
sitive dynamics in both mental and physical health para-
meters in the three observation groups. The use of a fixed 
combination of Amlodipine and Lisinopril as a baseline 
of two-four component therapy for patients with high 
and very high risk of arterial hypertension, in comparison 
with the starting treatment regimens in the form of free 
combinations of Amlodipine and Lisinopril or Ramipril, 
was accompanied by significant (p<0.05-0.001) improve-
ments in a number of parameters of the patients’ quality of 
life: scales of physical functioning, pain, general health, 
social functioning, mental health. The indicated dynamics 
of the quality of life of patients with hypertension was 
associated with a significant (p<0.001) decrease in blood 
pressure in each of the studied groups at the end of the 
observation period.
Our data conceptually coincides with the results of the 
EXPERT program, which showed that the use of a fixed 
combination of Amlodipine and Lisinopril, as a replace-
ment for previous therapy with various ACE inhibitors, 
sartans and CCB, led to a rapid, pronounced safe decrease 
in blood pressure, improved quality of life in the majori-
ty of patients with previously uncorrected blood pressure 
(Glezer et al. 2014).
Thus, complex antihypertensive therapy of patients 
with high and very high risk hypertension during 14 
weeks improved the structural and functional parameters 
of the left ventricle, improved the quality of life of pa-
tients, and was safe in terms of influence on lipid, carbo-
hydrate and electrolyte exchanges. The greater manifesta-
tion of the positive dynamics of the above parameters was 
characteristic of patients of Group 3 comparing to those 
of Groups 1 and 2.
Pharmacoeconomic analysis of various options for 
complex pharmacotherapy of patients with high and 
very high risk hypertension
The following criteria of the efficacy of the treatment re-
quired for conducting a clinical and economic analysis 
were used: degree (mm Hg) of SBP and DBP reduction; 
the frequency of achieving target blood pressure in pa-
tients of Groups 1, 2 and 3 at the end of the 4th and 14th 
week of pharmacotherapy;
The total cost of pharmacotherapy in patients of Group 
1 by the end of the 4th weeks of treatment was 31,012.8 
rubles, at the end of the 14th weeks –  143890.6 rubles. 
(per patient – 775.3 rubles and 3597.3 rubles, respective-
ly). For patients of Group 2, the corresponding indicators 
Figure 2. Comparative influence of various pharmacotherapy regimens on the quality of life of patients with hypertension.
Note. ∆% – degree of change in percentage, PF – physical functioning, RPF – role physical functioning, P – pain, GH – general 
health, V – vitality, SF – social functioning, REF – role emotional functioning, MH – mental health, * – significance of differences, 
p<0.05, ** – significance of differences, p<0.01, *** –  significance of differences, p<0.001. 
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were equal to 31889.2 rubles and 150630.1 rubles (per 
patient – 797.2 rubles and 3765.7 rubles, respectively). 
In Group 3, the similar parameters amounted to 23753.8 
rubles and 105723.8 rubles, respectively (per patient – 
593.8 rubles and 2643.1 rubles, respectively). The results 
of the calculation by the method of “cost-effectiveness” 
of the cost of reducing blood pressure by 1 mm Hg and 
the cost of achieving the target level of blood pressure in 
one patient with the implementation of various options 
for pharmacotherapy in different periods of treatment are 
presented in Figure 3.
Minimizing costs when using a fixed combination of 
Amlodipine and Lisinopril compared with the free com-
binations of Amlodipine with Ramipril or Lisinopril, 
depending on the chosen efficacy criterion, led to mini-
mization of costs from 18.1 rubles to 148.1 rubles per 
patient.
Our data match the results of studies on assessing the 
introduction of fixed combinations of drugs in the ma-
nagement of patients with hypertension with both initial 
therapy and low effecacy of previous strategies. Those 
studies demonstrated the cost-effectiveness of such an 
approach. It turned out that the separate administration 
of drugs in comparison with the fixed combination of the 
same substances was accompanied by significantly bigger 
(up to 65%) total costs for patient management. At the 
same time, the patients’ adherence to the treatment (calcu-
lated according to the implementation of prescription for-
mulations in the pharmaceutical database) was by 14.4% 
higher in the group treated with the drugs in the form of 
fixed combinations (Filippi et al. 2009, Mori et al. 2006).
Different types of pharmacoeconomic studies indica-
te that when using fixed combinations of drugs, impro-
vement in BP control is accompanied by a decrease in 
the total cost of providing medical care compared to the 
same, but separate combinations, primarily due to a de-
crease in the number of hospitalizations, visits to doctors, 
costs of other drugs (Kobalava et al. 2007).
Thus, the use of the fixed combination of Amlodipi-
ne and Lisinopril as a starting therapy, as well as when 
transferring patients with high and very high risk of hy-
pertension to the third and fourth stages of treatment, in 
comparison with alternative pharmacotherapy regimens, 
provided the least expensive treatment option.
Conclusion
The study investigated the method of personalization of 
pharmacotherapy of patients with high and very high risk 
arterial hypertension, based on the determination of the 
oxidative metabolism phenotype. When a slow or very 
slow phenotype of oxidative metabolism is detected in 
patients, it is preferable to administer Amlodipine with 
Lisinopril or Ramipril to ensure the greatest degree of hy-
potensive effect in this cohort, compared with patients in 
the phenotypic group with a high rate of oxidative biot-
ransformation.
Using the developed regression equations allows de-
termining the predicted degree of hypotensive effect of 
the studied options of starting pharmacotherapy (com-
bination of Amlodipine with Lisinopril or Ramipril) of 
patients with arterial hypertension of high and very high 
risk, which makes it possible to further individualize the 
treatment of the specified patient population.
In patients with arterial hypertension of high and very 
high risk, the pharmacodynamic and pharmacoecono-
mic advantage of the fixed combination of Amlodipine 
and Lisinopril is shown both as a starting treatment opti-
Figure 3. The average cost (rub.) of reducing SBP (A), DBP (B) 
by 1 mm Hg and the cost of achieving the target blood pressure 
(C) in one patient in each of the studied groups at different peri-
ods of observation.
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on and in combination with drugs of the third and fourth 
stages of treatment, compared with the free combinati-
ons of the studied drugs. This advantage was expressed 
in a significantly more significant hypotensive effect, an 
earlier achievement of the target blood pressure level, a 
significantly higher degree of regression of left ventricu-
lar myocardial hypertrophy, a significant improvement 
in a number of patients’ quality of life indicators: physi-
cal functioning, pain, general health, social functioning, 
mental health, and it was also characterized by the lowest 
cost-effectiveness ratios according to various criteria of 
the hypotensive effect.
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